What happened with the FDA and compounded GLP-1s, and who is still operating legally?

The situation with the FDA and compounded GLP-1s has been complex and evolving, driven by the immense demand for these medications (like Ozempic, Wegovy, Mounjaro, and Zepbound) and subsequent supply shortages.

Here's a breakdown of what happened and who is still operating legally:

What Happened with the FDA and Compounded GLP-1s?

When demand for GLP-1 drugs like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) soared, especially for weight loss, official supply could not keep up. This created an environment where compounding pharmacies stepped in to fill the gap.

The FDA's primary concerns and actions have centered on patient safety and the integrity of the drugs:

1. Unauthorized Active Pharmaceutical Ingredients (APIs):

   • The Major Issue: Many compounding pharmacies began using semaglutide sodium or semaglutide acetate to compound versions of semaglutide. The FDA has repeatedly warned that these are different salt forms of semaglutide than the base semaglutide used in the FDA-approved drugs (Ozempic and Wegovy).
   • Why it Matters: Semaglutide sodium and acetate have not been evaluated for safety and efficacy by the FDA. There's no guarantee they work the same way, have the same side effect profile, or are absorbed similarly. The FDA has stated these salt forms are not the same as the active ingredient in approved semaglutide products.
   • The FDA has stated that compounding of semaglutide is generally not permissible unless there is a genuine shortage of the FDA-approved drug and the compounder is using the exact same active ingredient as the approved drug, not a different salt form.

2. Purity and Sterility Concerns: Compounded drugs do not undergo the same rigorous FDA review for safety, effectiveness, and quality that commercial drugs do. There have been reports of adverse events, including hospitalizations, linked to non-sterile compounded products or products with incorrect dosages.

3. Misleading Marketing: Some compounding pharmacies or telehealth platforms have marketed their compounded versions as "generic Ozempic" or "generic Wegovy," which is inaccurate and misleading. There are currently no FDA-approved generic versions of these drugs.

4. Enforcement Actions: The FDA has sent numerous warning letters and cease and desist letters to pharmacies and telemedicine companies marketing or selling compounded GLP-1s with unapproved ingredients or making false claims. They've also updated guidance documents to clarify their stance.

In essence, the FDA is trying to protect consumers from potentially unsafe or ineffective products that haven't gone through proper testing and regulatory oversight.

Who Is Still Operating Legally (and Safely)?

This is crucial. The legality hinges on several factors, especially the active ingredient used and the context of compounding.

1. The Gold Standard (Always Legal & Safest):

• FDA-Approved Brand Name Medications:
  • Ozempic (semaglutide, diabetes treatment, often used off-label for weight loss)
  • Wegovy (semaglutide, FDA-approved for weight loss)
  • Mounjaro (tirzepatide, diabetes treatment, often used off-label for weight loss)
  • Zepbound (tirzepatide, FDA-approved for weight loss)
  • Why: These are rigorously tested, have known safety and efficacy profiles, and are manufactured under strict FDA oversight. You get these from a licensed healthcare provider and a licensed pharmacy.
  • Recommendation: If you can access and afford these, they are the safest and most reliable option.

2. Legitimate Compounding (Under Specific Conditions):

Compounding pharmacies are legal, regulated entities. However, their scope for compounding GLP-1s is very narrow due to the FDA's stance and the availability of approved products.

• Licensed 503A Compounding Pharmacies:

  • Legally Can: Compound a drug for an individual patient based on a specific prescription, only if there's a medical need (e.g., allergy to an inactive ingredient in the brand name, or a genuine, active shortage of the FDA-approved drug). They must use FDA-approved active pharmaceutical ingredients (APIs).
  • Cannot: Compound semaglutide sodium or semaglutide acetate under the guise of compounding semaglutide. They also cannot compound simply to offer a cheaper alternative or in anticipation of demand.
  • Why: These pharmacies operate under state boards of pharmacy oversight and follow specific federal guidelines. If they are compounding semaglutide, it must be using the base semaglutide API and meet the shortage criteria.
  • Recommendation: If your doctor prescribes a compounded GLP-1 due to a legitimate medical necessity (like an allergy to an ingredient in the brand name) and can verify the pharmacy is using the correct, FDA-approved API (not a salt form), this can be legal. Always ask your doctor and the pharmacy about the exact API being used.

• FDA-Registered 503B Outsourcing Facilities:

  • Legally Can: Compound larger batches of sterile drugs for "office use" or in anticipation of demand, often for hospitals or clinics. They must adhere to strict current Good Manufacturing Practices (cGMP), register with the FDA, and use FDA-approved APIs.
  • Cannot: Produce drugs using unapproved salt forms (like semaglutide sodium/acetate).
  • Why: These facilities have more federal oversight, similar to drug manufacturers, ensuring higher quality standards. Some reputable telehealth platforms partner with 503B facilities that claim to compound GLP-1s using the base semaglutide or tirzepatide API.
  • Recommendation: If considering a compounded GLP-1 via a telehealth platform, verify that they partner with an FDA-registered 503B outsourcing facility, and confirm unequivocally that the facility is using the base semaglutide or tirzepatide API, not a salt form. Ask for proof or documentation of their API sourcing.

Who to Be Wary Of / Avoid:

• Any pharmacy or platform selling "generic Ozempic" or "generic Wegovy." These do not exist.
• Any pharmacy or platform openly advertising or admitting to using "semaglutide sodium" or "semaglutide acetate." The FDA considers these unapproved for compounding semaglutide.
• Companies that don't require a thorough medical consultation and prescription from a licensed U.S. physician.
• Websites selling GLP-1s directly without a prescription or a clear connection to a licensed pharmacy.
• Prices that seem too good to be true. Quality, regulated medications are expensive.

In summary: While compounding pharmacies are legal, the specific conditions under which they can legally compound GLP-1s are very strict. Your safest bet is always the FDA-approved brand-name medications. If you explore compounded options, ensure extreme due diligence regarding the active ingredient and the legitimacy of the compounding facility.

Always consult with a licensed healthcare professional to discuss your medical needs and the safest, most appropriate treatment options for you.